Search Results - "Rocha‐Lima, Caio Max S."

A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors by Cleary, James M., Lima, Caio Max S. Rocha, Hurwitz, Herbert I., Montero, Alberto J., Franklin, Catherine, Yang, Jianning, Graham, Alison, Busman, Todd, Mabry, Mack, Holen, Kyle, Shapiro, Geoffrey I., Uronis, Hope

“…Summary Purpose : To investigate the safety, optimal dosing, pharmacokinetics and clinical activity of a regimen of navitoclax (ABT-263) combined with…”
Get full text

Comparison of survival for metastatic pancreatic cancer patients treated with CPI-613 versus resected borderline-resectable pancreatic cancer patients by Mangieri, Christopher W, Valenzuela, Cristian D, Solsky, Ian B, Erali, Richard A, Pardee, Timothy, Lima, Caio Max S Rocha, Howerton, Russell, Clark, Clancy J, Shen, Perry

“…Treatment of advanced pancreatic adenocarcinoma remains suboptimal. Therapeutic agents with a novel mechanism of action are desperately needed; one such novel…”
Get full text

Preoperative docetaxel/cisplatin/5-fluorouracil chemotherapy in patients with locally advanced gastro-esophageal adenocarcinoma by Bayraktar, Ulas Darda, Bayraktar, Soley, Hosein, Peter, Chen, Emerson, Koniaris, Leonidas G., Rocha-Lima, Caio Max S., Montero, Alberto J.

“…Perioperative chemotherapy plus surgery improves survival compared to surgery alone in GE junctional (GEJ) and gastric adenocarcinomas. The…”
Get full text

Does delay of adjuvant chemotherapy impact survival in patients with resected stage II and III colon adenocarcinoma? by Bayraktar, Ulas Darda, Chen, Emerson, Bayraktar, Soley, Sands, Laurence R., Marchetti, Floriano, Montero, Alberto Jose, Rocha‐Lima, Caio Max S.

“…BACKGROUND: It is unclear whether delays in commencing adjuvant chemotherapy after surgical resection of colon adenocarcinoma adversely impact survival…”
Get full text

Management of small cell lung cancer by Ciombor, Kristen Keon, Rocha Lima, Caio Max S

“…Small cell lung cancer (SCLC) is an aggressive type of lung cancer characterized by rapid growth and early metastasis. It is chemosensitive and radiosensitive,…”
Get full text

Devimistat (CPI-613) With Modified Fluorouarcil, Oxaliplatin, Irinotecan, and Leucovorin (FFX) Versus FFX for Patients With Metastatic Adenocarcinoma of the Pancreas: The Phase III AVENGER 500 Study by Philip, Philip A., Sahai, Vaibhav, Bahary, Nathan, Mahipal, Amit, Kasi, Anup, Rocha Lima, Caio Max S., Alistar, Angela T., Oberstein, Paul E., Golan, Talia, Metges, Jean-Philippe, Lacy, Jill, Fountzilas, Christos, Lopez, Charles D., Ducreux, Michel, Hammel, Pascal, Salem, Mohamed, Bajor, David, Benson, Al B., Luther, Sanjeev, Pardee, Timothy, Van Cutsem, Eric

“…Metastatic pancreatic adenocarcinoma (mPC) remains a difficult-to-treat disease. Fluorouarcil, oxaliplatin, irinotecan, and leucovorin (FFX) is a standard…”
Get full text

Phase 2 study of combination SPI-1620 with docetaxel as second-line advanced biliary tract cancer treatment by Kim, Richard, Chiorean, E Gabriela, Amin, Manik, Rocha-Lima, Caio Max S, Gandhi, Jitendra, Harris, William P, Song, Tao, Portnoy, David

“…Background: This multicentre, open-label study evaluated the efficacy and safety of SPI-1620, an analogue of endothelin-1, administered in combination with…”
Get full text

Therapy choices among older patients with lung carcinoma: An evaluation of two trials of the Cancer and Leukemia Group B by ROCHA LIMA, Caio Max S, HERNDON, James E, KOSTY, Michael, CLAMON, Gerald, GREEN, Mark R

“…Despite a greater risk of malignancy and a higher cancer mortality rate for patients age > 65 years, bias in accruing older patients to clinical trials…”
Get full text

Irinotecan Plus Gemcitabine Induces Both Radiographic and CA 19-9 Tumor Marker Responses in Patients With Previously Untreated Advanced Pancreatic Cancer by Rocha Lima, C. M. S.

Get full text

5-fluorouracil-induced coronary vasospasm by Shoemaker, Laura K, Arora, Umesh, Rocha Lima, Caio M

“…Cardiotoxicity is a rare but well-documented adverse effect of 5-fluorouracil (5-FU). The underlying cause of this side effect of 5-FU is uncertain. We present…”
Get more information

Docetaxel in the Management of Advanced Pancreatic Cancer by Lopes, Gilberto, Rocha Lima, Caio Max S.

“…The poor outcome of pancreatic cancer with conventional treatment options emphasizes the need for continued research. The benefits of gemcitabine in improving…”
Get full text

Metastatic colorectal cancer: systemic treatment in the new millennium by Coutinho, Anelisa K, Rocha Lima, Caio M

“…Colorectal cancer (CRC) is common in North America. Metastatic disease is present at diagnosis in 30% of the patients, and approximately half of early-stage…”
Get more information

Update on pancreatic cancer by Rocha Lima, Caio Max S, Centeno, Barbara

“…Pancreatic cancer remains the fourth leading cause of cancer deaths in males and females in the beginning of this new millennium. The 5-year survival for all…”
Get full text

Successful treatment of anal gland adenocarcinoma with combined modality therapy by Warsch, Sean, Bayraktar, Ulas Darda, Wen, B-Chen, Zeitouni, Joseph, Marchetti, Floriano, Rocha-Lima, Caio Max S, Montero, Alberto J

Get full text

Topoisomerase I-based nonplatinum combinations in non-small-cell lung cancer by Rocha Lima, Caio Max S, Joppert, Marcos G

“…Lung cancer is the leading cause of cancer-related death in males and females in the United States. Most patients have advanced disease at diagnosis…”
Get more information

Molecular rationale for ERK and EGFR inhibition in colorectal cancer by Yeatman, Timothy Joseph, Davis, Thomas, Yang, Mingli, Schell, Michael J., Wang, Heiman, Rocha Lima, Caio Max S., Pledger, Jack

“…Abstract only 679 Background: Mutational activation of the RAS pathway occurs in >50% of human CRC tumors, and to date has been difficult to overcome. We…”
Get full text

Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer by ROCHA LIMA, Caio Max S, SAVARESE, Diane, ELFRING, Gary L, LOCKER, Paula K, COMPTON, Linda D, MILLER, Langdon L, GREEN, Mark R, BRUCKNER, Howard, DUDEK, Arkadiusz, ECKARDT, John, HAINSWORTH, John, YUNUS, Furhan, LESTER, Eric, MILLER, William, SAVILLE, Wayne

“…This phase II, multicenter, open-label, single-arm study evaluated the efficacy and safety of irinotecan and gemcitabine as combination chemotherapy for…”
Get full text

Beyond pancreatic cancer: irinotecan and gemcitabine in solid tumors and hematologic malignancies by Rocha Lima, C M, Urbanic, J J, Lal, A, Kneuper-Hall, R, Brunson, C Y, Green, M R

“…Non-platinum combinations including gemcitabine and irinotecan (Gemzar; Eli Lilly and Company, Indianapolis, IN) for the management of a variety of…”
Get more information

Identification of mutation biomarkers underpinning colon cancer sidedness and cetuximab sensitivity by Yeatman, Timothy Joseph, Yang, Mingli, Schell, Michael J., Loboda, Andrey, Nebozhyn, Michael, Li, Jiannong, Teer, Jamie K., Rocha Lima, Caio Max S., Pledger, Jack

“…Abstract only 629 Background: Currently, extended RAS testing ( KRAS/ NRAS) in colorectal cancer (CRC) patients identifies only non-responders to EGFR…”
Get full text

Translating landmark trial-based evidence to the front lines of care for pancreatic cancer: the evolving trial-based and guideline-supported role for nanoliposomal topoisomerase inhibitors in metastatic pancreatic adenocarcinoma by Lima, Caio M S R

Get full text